VASO Vaso Corporation (QX)

Vasomedical, Inc. ("Vasomedical") (OTCBB:VASO), a world leader in the noninvasive treatment of cardiovascular diseases, today announced a reorganization of its Board of Directors to realign its leadership to better position the company for a more diversified business portfolio, including its exclusive sales representative agreement for select diagnostic imaging products recently signed with GE Healthcare. Mr. Simon Srybnik, upon his appointment as Acting Chairman of the Board, said that "Vasomedical's strategy of growth includes exploration of new and exciting opportunities to meet current and future needs of the worldwide medical marketplace. Restructuring our Board at this time should enable the company to realize its growth potential and to achieve greater shareholder value. I look forward to the active involvement of our directors as we begin to undertake this additional direction in close collaboration with GE Healthcare."

In addition to Mr. Srybnik, the new Board of Directors consists of current members Dr. Jun Ma, President and CEO, Mr. Behnam Moveseghi, CPA, and Dr. Derek Enlander. Joining the Board at this time is Mr. William Dempsey, former owner and Managing Director of Cardiac Services Ireland Ltd., a healthcare and distribution company in Ireland and the UK. It is the Company's intent that Mr. Dempsey, with his extensive experience in medical device sales channels, will provide strategic input and directorial oversight for the Company's new sales representation business.

The Board of Directors and the Company express their greatest appreciation to the former directors who resigned last week as part of this structured reorganization, including Mr. Abraham E. Cohen, who had served as its Chairman of the Board for 15 years; Dr. John Hui, a founder of Vasomedical; and Mr. Photios Paulson, who had not only served on the Board but also as President and CEO at different times. Dr. Hui will remain with the company as Chief Technology Officer as well as Chairman of our newly formed Advisory Committee, which also includes Mr. Paul Hannigan, a former Managing Director of Cardiac Services in Ireland, and others to be added shortly.

"In addition to continuing to promote EECP therapy and make it available to more people around the world, our reorganization at this time positively demonstrates Vasomedical's commitment to move beyond and rise above all challenges facing companies in our industry today, and in concert with our strategic relationships like GE Healthcare, to deliver on the promise of increasing patient access to improved and lower cost healthcare," commented Dr. Jun Ma. "At Vasomedical, we believe that what we do today will make a difference tomorrow."

About Vasomedical

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP® is a registered trademark for Vasomedical's enhanced external counterpulsation system.   Through its sales representative agreement with GE Healthcare, the Company is also engaged as an exclusive sales representative for certain GE Healthcare products. Additional information is available on the Company's website at www.vasomedical.com

VasoHealthcare™, a wholly owned subsidiary of Vasomedical Inc., is a professional sales representation company offering vendors an alternative third party sales channel. Additional information is available at www.vasohealthcare.com. The Vasomedical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7673

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate", "believes", "estimate", "expect", "explore", "should", "intend", "projects", "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the ability to perform under the agreement with GE Healthcare, the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

CONTACT:  Vasomedical, Inc.
          Dr. Jun Ma, President and CEO
            516-997-4600
          David Singh, CFO
            516-997-4600
          Investor Relations:
            customerservice@vasomedical.com